Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000488256 | SCV000574815 | likely pathogenic | not provided | 2016-09-30 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000667007 | SCV000791393 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2017-05-09 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000488256 | SCV001590414 | pathogenic | not provided | 2023-10-09 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Trp2841*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with Usher syndrome and retinitis pigmentosa (PMID: 26969326, 27353947, 27460420, 28559085, 30924848). ClinVar contains an entry for this variant (Variation ID: 424934). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV003449252 | SCV004182796 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001834579 | SCV004182798 | likely pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003449252 | SCV004208348 | pathogenic | Retinitis pigmentosa 39 | 2024-02-27 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001834579 | SCV002090818 | pathogenic | Usher syndrome type 2A | 2020-09-22 | no assertion criteria provided | clinical testing |